Factor Therapeutics Limited, formerly Tissue Therapies Limited, is a biotechnology company. The Company's principal activities include the development and commercialization of its intellectual property in wound care.
Tissue Therapies (ASX:TIS), a biomedical technology company developing effective treatments for wound healing, today announces its intention to develop VitroGro(R) ECM as a pharmaceutical worldwide for wound healing, and approval will be concurrently sought from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Asian Activities Report for November 1, 2011 includes: Montezuma Mining Company Ltd (ASX:MZM) reports outstanding copper results from a recently completed 19-hole drilling programme at the Company's 100% owned Butcherbird Copper Project in Western Australia; Hannans Reward Ltd (ASX:HNR) provides an update on its drilling program currently underway at the Jigalong Project; Biomedical company, Tissue Therapies Limited (ASX:TIS) says today that the VitroGro(R) synthetic protein has been classified as a biologic product by the US Food and Drug Administration; Navigator Resources Limited (ASX:NAV) has achieved the production milestone of 100,000 ounces of gold poured since it commenced operation at the Company's Bronzewing Gold Project, located 960km northeast of Perth.
Asian Activities Report for September 30, 2011 includes: Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream; India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine; Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt; Tissue Therapies Limited (ASX:TIS) will start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012; Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225; Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100.
Australian Market Report of October 6, 2010 includes: Quantum Resources Limited (ASX:QUR) Gardner Range exploration program is underway; Tissue Therapies Limited (ASX:TIS) was granted the third core VitroGro (R) patent in US; International Finance Corporation commits to further investment in Gryphon Minerals Limited (ASX:GRY); Alkane Resources Limited (ASX:ALK) drill results confirm continuity of gold mineralisation in NSW.
The Australian stock market opened lower on Monday, following mixed leads from overseas markets. In early trade, the S&P/ASX200 index was down 0.41 per cent, at 4547.4 points, while All Ordinaries had fallen 19 points, or 0.41 per cent, to 4567.3 points.
Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that Ms Sue MacLeman will step down from the role of Chief Executive Officer (CEO) and Managing Director to pursue other opportunities. She has agreed however to stay actively involved with Benitec as a Strategic Advisor at this exciting time for the Company. A transition arrangement has been put in place. Mr Mel Bridges and Dr John Chiplin will both move to Executive Director roles within the Company and the Board will be further strengthened in the coming months.
Biomedical company, Tissue Therapies Limited (ASX: TIS) today announced that formal approval has been received from the Trafalgar Ethics Board in Toronto to proceed with the human clinical trial of VitroGro for the treatment of diabetic and venous ulcers scheduled to begin later this month.
TISSUE THERAPIES LIMITED (ASX: TIS) - Small Caps Forum<br/>Interview with Dr Stephen Mercer, CEO; Boardroomradio is pleased to announce that TISSUE THERAPIES LIMITED (ASX: TIS) has published an audio
